Cutting-edge genomic array advances global pharmacogenomic research

Thermo Fisher Scientific responds to the demand for a more inclusive representation of the human genome with the introduction of its latest and most diverse genomic array, the AxiomTM PangenomiX Array*. Built upon the first draft of the pangenome, which incorporated full genetic blueprints from 47 individuals worldwide, this high-throughput microarray offers unparalleled coverage for population-scale disease investigations and pharmacogenomic research.

The prevailing large-scale genomic datasets primarily rely on European and Caucasian cohorts, limiting the understanding of genetic variations in other populations, including African, Asian, and mixed populations. The PangenomiX Array aims to address this gap by providing comprehensive genomic insights across diverse ethnicities, supporting proactive healthcare models emphasising the role of genetics in disease risk and drug response.

Distinguishing itself as the only research solution combining four assays in a single test - SNP genotyping, whole genome copy number variant detection, fixed copy number discovery, blood, and HLA typing - the PangenomiX Array facilitates advancements in disease risk and detection, population-scale research programs, ancestry testing, wellness assessments, drug efficacy trials, and drug development endeavours.

The array incorporates clinically relevant pharmacogenomic markers and pathogenic variants, offering researchers improved whole-genome imputation and a high degree of diversity for testing across various ethnic backgrounds. Already utilised in the analysis of nearly half a million ethnically diverse samples at a prominent US biobank, the PangenomiX Array contributes to inclusive research studies focused on preventing, diagnosing, and treating diseases.

Kim Caple, President of Genetic Sciences at Thermo Fisher Scientific, commented: “The PangenomiX Array marks a significant stride in diversifying genomic datasets, propelling population-scale disease testing to unprecedented levels. This development holds long-term implications for our understanding of human disease, drug development, pharmacogenomics, and ancestry. With its extensive coverage, cost-effectiveness, accuracy, and reproducibility, the array builds on our three decades of dedicated microarray research, aiming to empower research that enhances people's longevity and well-being.”

More information online